The Fisherman became Bridgeport's primary logo in July. The New York Islanders' original version in the 1990s provided more ...

Pfizer stock (NYSE: PFE) is trading at about $30 per share, not far from the lows seen in recent years. Could the stock rise by over 2x in value over the next few years? Does this sound a bit ...

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following ...

DelveInsight's Hormone Replacement Therapy Market Insights report provides the current and forecast market analysis, ...

The withdrawal is the latest headwind for Pfizer and its CEO Albert Bourla. Investors have punished the company as it ...

Sept 26 (Reuters) - The European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer's ...

U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...

Pfizer chief executive Albert Bourla said in an interview the progress was slower than he had hoped because "few countries ...

Leading CDK 7 inhibitor companies such as Carrick, Pfizer, Menarini Group ... which may limit their clinical use or require the development of combination therapies to mitigate side effects.

In a report released today, Carter Gould from Barclays maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of ...

DelveInsight's CDK 7 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, ...